new glp-1 receptor agonists Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Agonists: A Scoping Review Revolutionizing obesity treatment: The emerging

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects

polycystic ovarian syndrome, immigration 10 years prior, age over 95 years, eGFR below 30 mL/min/1.73 m 2 , heart failure, missing prebaseline HbA1c, HbA1c level below 42 mmol/mol, or gestational diabetes

Out of the organizations that cover GLP-1s for weight loss, 37% said it is important to employee satisfaction, while 26% said this coverage is very important

Available from: Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al

However, general practitioners are responsible for the management of type 2 diabetes in the UK, meaning that this is unlikely to be an important source of misclassification.45 Additionally, exposure misclassification is possible given that prescriptions in the CPRD are those written by general practitioners and not those filled by the patient